Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma

Abstract excerpt

Recurrence of solid tumors renders patients vulnerable to advanced, treatment-refractory disease state with mutational and oncogenic landscape distinctive from initial diagnosis. Improving outcomes for recurrent cancers requires a better understanding of cell populations that expand from the post-therapy, minimal residual disease (MRD) state. We profile barcoded tumor stem cell populations through therapy at...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Glioma Diagnosis and Treatment
• Share to Single-cell and spatial transcriptomics